Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06577987 · ClinicalTrials.gov registry record · Phase 1

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

A Phase 1 study of Cancer and Lung Cancer, sponsored by Circle Pharma.

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
10
Study locations

NCT06577987 is a Phase 1 study of Cancer and Lung Cancer that is actively recruiting participants, run by Circle Pharma. The registered enrollment target is 220 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06577987, a Phase 1 study of Cancer and Lung Cancer, is actively recruiting participants, sponsored by Circle Pharma.

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
10
Study locations

Study Summary

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.

Conditions Studied

Cancer Lung Cancer Advanced Solid Tumor Triple Negative Breast Cancer Breast Neoplasms Metastatic Solid Tumor Neuroendocrine Tumors Neuroendocrine Carcinoma Refractory Solid Tumor RB1 Gene Mutation

Interventions

  • DRUG CID-078 Monotherapy

Study Locations (10)

Texas

  • MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Florida

  • Florida Cancer Specialists - Sarasota

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • START Midwest - Grand Rapids

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

Ohio

  • UH Seidman Cancer Center - Cleveland

Oregon

  • Oregon Health and Science University - Portland

Tennessee

  • Sarah Cannon Research Institute - Nashville

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-08-14
Est. Completion 2027-03-14
Phase Phase 1

Sponsor

Circle Pharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06577987

The ClinicalTrials.gov registry entry for NCT06577987 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Circle Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which CID-078 Monotherapy is the first listed.

NCT06577987 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06577987 about?

NCT06577987 is a clinical study titled "Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies". This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.

What is the current status of trial NCT06577987?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-08-14. Estimated completion is 2027-03-14.

What conditions does trial NCT06577987 study?

This clinical trial studies the following conditions: Cancer, Lung Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Breast Neoplasms.

What interventions are being tested in trial NCT06577987?

The interventions under investigation include: CID-078 Monotherapy (DRUG).

Who is sponsoring clinical trial NCT06577987?

This trial is sponsored by Circle Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06577987 being conducted?

This trial has 10 study locations across Florida, Massachusetts, Michigan, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.